The small MAF transcription factor MAFG co-opts MITF to promote melanoma progression
Vera, O.; Martinez, M.; Soto-Vargas, Z.; Wang, K.; Xu, X.; Ruiz-Buceta, S.; Mecozzi, N.; Chadourne, M.; Posorske, B.; Angarita, A.; Bok, I.; Liu, Q.; Murikipudi, H.; Kim, Y.; Messina, J. L.; Tsai, K. Y.; Major, M.; Lau, E. K.; Yu, X.; Ibanez-de-Caceres, I.; Karreth, F. A.
Show abstract
Transcription factor deregulation potently drives melanoma progression by dynamically and reversibly controlling gene expression programs. We previously identified the small MAF family transcription factor MAFG as a putative driver of melanoma progression, prompting an in-depth evaluation of its role in melanoma. MAFG expression increases with human melanoma stages and ectopic MAFG expression enhances the malignant behavior of human melanoma cells in vitro, xenograft models, and genetic mouse models of spontaneous melanoma. Moreover, MAFG induces a melanoma phenotype switch from a melanocytic state to a more dedifferentiated state. Mechanistically, MAFG interacts with the lineage transcription factor MITF which is required for the pro-tumorigenic effects of MAFG. MAFG and MITF co-occupy numerous genomic sites and MAFG overexpression influences the expression of genes harboring binding sites for the MAFG[~]MITF complex. These results establish MAFG as a potent driver of melanomagenesis through dimerization with MITF and uncover an unappreciated mechanism of MITF regulation. Significance statementMITF is critically involved in melanoma progression and phenotype switching. We discovered that MAFG interacts with MITF to influence expression of MITF target genes and facilitate a shift toward a dedifferentiated melanoma cell state. This study demonstrates that MAFG promotes melanomagenesis by influencing MITF activity, an unappreciated mechanism of MITF regulation.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- A targetable PREX2/RAC1/PI3Kβ signalling axis confers resistance to clinically relevant therapeutic approaches in melanoma 97%
- EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes 96%
- ZIP9 is a Druggable Determinant of Sex Differences in Melanoma 96%
Similar papers in this journal
- Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers 97%
- FRA1 drives melanoma metastasis through an actionable transcriptional network 97%
- ZEB1 controls a lineage-specific transcriptional program essential for melanoma cell state transitions 95%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.